As the third phase of vaccination starts from May 1 for those above 18 and under 45, EBNW Story hereby brings in a complete analysis and comparison of two vaccines Covaxin and Covishield.
The first phase of vaccination drive started on January 16 in India where front line workers including medical staff, police personnel and so on were allowed to take the vaccination jabs. The second phase of COVID-19 vaccination started on March 1, in which people over the age of 60 and those above 45 with associated comorbidities were allowed to take the life-saving shots. The third phase started from April 1 where people above 445 years of age were allowed to take jabs.
Covaxin | Covishield |
- Covaxin has been developed by Hyderabad-based Bharat Biotech International Ltd in association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
| - Covishield is developed by the Oxford-AstraZeneca and is being manufactured by the Serum Institute of India (SII).
|
- Covaxin is an inactivated vaccine, which has been prepared on a tried and tested platform of dead viruses.
| - Covishield has been prepared using the viral vector platform which is a totally different technology.
|
| |
- Covaxin can be stored at 2-8 degrees Centigrade, which is a household refrigerator temperature.
| - Covishield can also be stored at 2-8 degrees Centigrade, which is a household refrigerator temperature.
|
- Priced at Rs 600 for state governments and Rs 1200 for private hospitals.
- Rs 250 for 45 and above in private hospitals
| - Priced at ₹400 per dose to states and ₹600 per dose to private hospitals
|
- The effectiveness of the Covaxin is 81% according to interim 3rd phase trial results
| - The effectiveness of the Covishield vaccine is nearly 90% as per the global reports and Covaxin’s 81% according to interim 3rd phase trial results
|
.
